MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes. Discovered by OSI’s diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies. Pre-clinical data on PSN821 was the subject of an oral presentation at this year’s American Diabetes Association meeting in San Francisco, CA in June. PSN821 is the third development candidate discovered in-house that the Company has moved into clinical development this year. PSN602, OSI’s first anti-obesity agent to enter the clinic commenced a Phase I trial in June and OSI-027, the Company’s anti-cancer TORC1 and TORC2 inhibitor began a Phase I trial in July.
